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It is well known that cancer patients have signifi-
cantly increased risk of developing venous throm�o-
em�olism �VTE��. The most strongly throm�osis-asso-
ciated tumors are mucin-producing adenocarcinomas�� 
cancer of pancreas�� �rain�� ovary�� colon [���]. In fact�� 
a�out ��% of all cancer patients develop throm�osis 
during course of the malignant disease [�]. Moreover�� 
the incidence of deep vein throm�osis may increase in 
some type of cancer�� thus it ranges from ��% to 4�% 
for patients with urological or gynecological malignan-
cies in postoperative periods [4].
The clinical VTE is associated with worse outcomes 
in cancer patients�� including increased mortality [��6]. 
Among non-cancer causes of death in patients with ma-
lignancy. Throm�osis takes leading place. A.A. Khorana 
et al. [��] had estimated the annualized death rate for VTE 
in population of cancer patients�� which represented a 
4��-fold elevation over the general population.
Although R. Virchow originally descri�ed a triad 
of causes of throm�osis �stasis�� vessel wall injury 
and hypercoagula�ility�� more than a century ago�� the 
mechanism �y which tumors may alter haemostasis is 
still not completely understood. It is known that cancer 
cells can activate the clotting system directly�� which 
leads to throm�in formation�� or indirectly �y stimulating 
endothelial cells to produce procoagulants. Moreover�� 
pathogenetic mechanisms of hypercoagulation realized 
through additive risk factors in case of cancer patients: 
treatment with some antineoplastic agents�� immo�iliza-
tion�� central venous line �CVL���� infectious complications�� 
surgical interventions�� — all of them are acquired.
In recent years many inherited throm�ophilia traits 
have �een descri�ed [8��]. Most common of them are 
resistance to activated protein C�� which is caused �y 
mutation of the factor V �Factor V Leiden or FVL���� pro-
throm�in G�����A mutation and MTHFR C6����T variant 
of methylene-tetrahydrofolate reductase gene [��]. All 
of these mutations are point mutation�� resulted from 
a single nucleotide su�stitution in DNA. They differ 
from each other �y pathological mechanism �ut all of 
them alter haemostatic system and disrupt regulatory 
pathways that limit the coagulation cascade.
The role of hereditary throm�ophilia in cancer 
patients with throm�osis is still unclear. Moreover�� a 
lot of literature data show the association of cancer 
and throm�osis in adult patients �ut little is known 
a�out etiology of VTE in children with cancer. One of 
the possi�le reasons for that is higher frequency of 
VTE in adult than in children [�����]. That is why the 
purpose of our study was to determine the hereditary risk 
factors that contri�ute to the development of throm�osis 
in pediatric cancer patients.
MATHERIALS AND METHODS
Patients. Ninety-nine patients aged neonate to 
�� years with malignant disorders were analyzed in 
this study retrospectively. All patients were admitted 
in Belorusian Center for Pediatric Oncology and He-
matology�� Minsk�� Belarus for diagnosis and treatment. 
Cases ��� patients�� were identified if patients were di-
agnosed with episode of VTE during treatment. Others 
�8� patients�� were identified as controls. The study was 
approved �y Ethic Committee of the Center.
Patients from �oth groups were evaluated for 
congenital and acquired risk factors for throm�osis�� 
and patients were screened for FVL�� prothrom�in 
G�����A�� MTHFR C6����T mutations�� ATIII�� presence 
of anti-phospholipid anti�odies �APA��.
THROMBOTIC COMPLICATIONS DURING CANCER TREATMENT 
IN CHILDREN
N.V. Lipay*,**, V.V. Dmitriev, M.B. Borisenok
Belorusian Center for Pediatric Oncology and Hematology, Minsk, Republic Belarus
Aim: To determine the hereditary risk factors contributing to the development of thrombosis in children with cancer. Methods: 
Sensitive PCR- restriction fragment length polymorphism assay. Results: There has been shown significant prevalence of factor 
V leiden (FVL) in the group of 19 patients with thrombosis (P = 0.0004). The prothrombin G20210A mutation was not detected 
in 19 cases and 80 controls, indicating low frequency of this mutation among Belarusian population. The MTHFR C677T mutation 
was found in both cases and controls and has approximately the same frequencies in both groups (47.4% and 55.0% accordingly). 
Conclusion: Clinical condition, coagulation status, volume of haemostatic therapy and clinical evidence of sepsis, as well as duration 
of catheterization were not significant as predisposing to thrombosis factors. We have shown that the leading risk factors for venous 
tromboembolism (VTE) in children with cancer are mutation FVL, prolonged immobilization or both immobilization and indwelling 
femoral venous catheter. Cancer patients affected with VTE during treatment are potential candidates for genotyping assay for FVL 
mutation, as the former may determine duration of anticoagulation therapy and administration of secondary prophylaxis.
Key Words: venous thromboembolism, cancer, children, Factor V Leiden, prothrombin G20210A, MTHFR C677T.
Received: July 11, 2007. 
*Correspondence:  E-mail: fulltextfor@tut.by 
 Tel./Fax: (+375)-17-265-42-22 
Abbrevations used: VTE — venous thromboembolism; FVL – Factor V 
Leiden; MTHFR – methylene-tetrahydrofolate reductase; APA – an-
tiphospholipid antibodies;CVL – central venous line; FDP – fibrin/
fibrinogen degradation products; SFMC – soluble fibrin monomer 
complexes; SIRS – systemic inflammatory response syndrom. 
**Author was awarded on the Conference of young Scientists hold 
in IEPOR, Kyiv, Ukraine, 2007.
Exp Oncol �����
���� ��� �������
��� Experimental Oncology ���� ��������� ����� ��eptem�er��
Diagnosis of VTE was confirmed �y Doppler-ultra-
sonography.
The presence of risk factors provoking throm�osis 
was recorded. These were: � — placement of cen-
tral vein catheter �CVC���� � — haemostatic therapy�� 
� — prolonged immo�ilization �> � week���� 4 — surgery�� 
� — administration of L-Asparaginase Medac with 
prednisolone in the ALL patients�� 6 — clinical symptoms 
of �ystemic Infammatory Response �yndrom ��IR����� 
�� — presence of APA�� 8-inhereted throm�ophilia.
Sensitive PCR- restriction fragment length 
polymorphism assay. DNA from leucocytes of 
peripheral �lood samples was isolated �y standard 
phenol-chloroform method [�4]. DNA analysis for FVL�� 
prothrom�in G�����A�� MTHFR C6����T was performed 
according previously descri�ed methods with some 
modifications [����8]. Briefly�� DNA was amplified with 
primers �Ta�le ��� in reaction mix with final volume �� μl. 
In each PCR reaction 8����� ng DNA template�� ��� nM 
of each primer�� �.� mM MgCl��� �.� mM dNTP�� �U Tag-
polymerase �Promega�� were used. PCR conditions 
were: initial denaturation at �4 °C for � min�� followed �y 
�� cycles of amplification at �4 °C for �� s�� �6� °C for 
FVL�� ��� °C for G�����A�� �8 °C for MTHFR C6����T�� for 
4� s�� ��� °C for � min and a final extension at ��� °C for 
� min. Five units of �Mnl� for FVL�� HindIII for G�����A�� 
Hinf� for MTHFR C6����T�� restriction endonuclease 
were incu�ated with �� μl of amplified DNA at ��� °C for 
�.� h. The digested products were electrophoresed 
on �.�% agarose gel to detect wild�� homozygous and 
heterozygous types.
Table 1. Oligonucleotide primers used in PCR analysis of FVL, G20210A, 
MTHFR C677T mutations
Gene Primer Sequence
Factor V
Forward 5’-TGC CCA GTC CTT AAC AAG AAC-3’
Reverse 5’-CTT GAA GGA AAT GCC CCA TTA-3’
Factor II
Forward 5’-TCT AGA AAC AGT TGC TGC CTG GC-3’
Reverse 5’-ATA GCA CTG GGA GCA TTG AAG C-3’
MTHFR
Forward 5’-TGA AGG AGA AGG TGT CTG CGG GA-3’
Reverse 5’-AGG ACG GTG CGG TGA GAG TG-3’
Clotting parameters �APTT�� PTT�� TT�� Fi�rinogen�� 
D-dimer�� were measured on ACL-���� �IL�� U�A��. 
Hemoglo�in�� platelet and WBC count were measured 
on ABX Micros-6� �ABX Diagnostics�� France��. Plasma 
level of �FMC and FDP were measured using special 
kit �Roche�� France��. Anti-phospholipid anti�odies �IgG 
and IgM�� were measured with the help of the Assera-
chrom APA kit �Diagnostica �tago�� France��
Statistical analysis was performed using program 
�tatistica 6.�. Data is depicted as mean and ��th and 
���th percentiles or as mean ± standard deviation in 
the case of normal distri�ution. Between-group allelic 
frequencies and differences in the position of cath-
eter were compared using χ�-test. In other cases two 
groups were compared �y the Mann — Whitney U-test. 
P value < ����� were considered significant.
RESULTS AND DISCUSSION
Throm�oses have �een revealed in a group of 
�� children with median age of �� years ��������� �Ta-
�le ���. Five out of �� were affected �y acute lympho�las-
tic leukemia�� 4 — �y acute myeloid leukemia�� 4 — �y 
Non-Hodgkin’s lymphoma�� 6 — �y solid tumors �� cases 
of Ewing’s sarcoma�� � cases of CN� tumor�� desmoid 
tumor and teratoma��. Throm�oses in this group oc-
curred equally frequent in �oys ���� and girls �����. None 
of children had VTE �efore treatment. All of them had 
only one episode of VTE during o�servation.
Table 2. Characteristics of cases and controls
Cases
n = 19
Controls
n = 80
Age at enter, years 15 (11–17) 10 (6–14)
Male/Female 1.1/1 2.8/1
Cancer type:
ALL
AML
NHL
Solid tumors
5
4
4
6
30
30
10
10
Genotype for MTHFR C677T, % 
Wild type
Heterozygous
Homozygous
52.6
47.4
0.0
45.0
45.0
10.0
Genotype for prothrombin  G20210A, %
Wild type
Heterozygous
Homozygous
0.0
0.0
0.0
0.0
0.0
0.0
Genotype for FV L, %
Wild type
Heterozygous
Homozygous
79.0
21.0
0.0
98.75
1.25
0.0
Number of risk factors for thrombosis 3,0 
(2,0–4,0)
3,0
(2,0–4,0)
As for genetic analysis�� our study showed significant 
prevalence of FVL in the group of patients with throm�osis 
�P = �.���4��. Four out of �� cases ���%�� were hetero-
zygous for FVL. Only one patient from 8� controls was 
FVL positive ��.��%��. This FVL positive patient with acute 
myeloid leukemia remained asymptomatic for VTE during 
�-years’ o�servation period. Nevertheless these findings 
suggest an association of FVL with increased risk of VTE. 
There are controversial and limited data a�out VTE in 
children with malignancy. Thus some authors confirm 
the association �etween throm�osis and inherited pro-
throm�otic state [�����]�� although the opposite opinions 
can �e found in literature as well [�����]. 
The prothrom�in G�����A mutation was not de-
tected in all �� patients�� indicating low frequency of this 
a�normality among Belarusian population. The MTHFR 
C6����T mutation was found in cases and controls and 
has approximately the same frequencies in �oth groups 
�4��.4% for cases and ��.�% for controls��. Thus�� like other 
researchers�� in this work we demonstrate that there is no 
association �etween MTHFR C6����T and VTE [��].
The clinic manifestation of �ystemic Inflamma-
tory Response �yndrome ��IR��� among children with    
throm�oses was reported in 4 out of �� cases. In the 
second group symptoms of �IR� were reported for ���     
patients and 4� children had no clinical evidence of 
sepsis. �tatistical analysis of the data revealed an as-
sociation �etween the fact of throm�osis and a�sence 
of clinical evidence of �IR� �Р = ����4���. However�� 
this interlinking �ecomes non-significant with the ap-
proximation of the Chi-square �y Yates’ correction �Р 
= ����8��. This fact allows us to state that the develop-
ment of throm�osis in children and clinical evidence of 
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sepsis has no essential value as predisposing factor. 
This o�servation contrasts with the data presented 
�y others�� e. g. Gurgey A. et al. [�4] indicated that the 
most frequent underlying disorder in children with non-
catheter-related throm�osis is infection.
The clinical condition of patients in compared 
groups was different. Among children without clinical 
evidence of throm�osis septic complications occurred 
more often than among children with throm�oses. 
For maintenance of homeostatic indices the patients 
of the control group required more intensive therapy�� 
although this trend was non-significant �Р > �������.
The evaluation of the haemostatic status of patients 
in compared to groups did not reveal significant differ-
ences in the majority of parameters �Ta�le ���. As it was 
mentioned a�ove half of controls had clinical evidence 
of �IR� as a result of cytopenia. In connection with that�� 
patients of the control group had higher level of fi�rino-
gen than cases �4.�� ± �.� g/l vs. �.4 ± �.4 g/l�� Р = �.��8��. 
For the same reasons the count of platelets and WBC 
of peripheral �lood were lower among controls: 8��.� ±         
��.� x ���/l and �.6 ± �.� x ���/l respectively in controls 
compared to �88.� ± ��.8 x ���/l and 4.�8 ± �.8 x ���/l 
respectively in cases �Р = �.�����. At the same time the 
extent of haemostatic therapy in controls was greater 
then in cases.
Table 3. Clotting parameters and haemostatic therapy in the children with 
and without thrombosis
Parameter Casesn = 19
Controls
n = 80 Significance
Activated partial thromboplastin 
time, ratio
1.05 ± 0.04 1.04 ± 0.02 n. s.
Prothrombine time, INR 1.2 ± 0.05 1.29 ± 0.04 n. s.
Thrombin time, ratio 1.29 ± 0.05 1.24 ± 0.5 n. s.
Fibrinogen, g/l 3.4 ± 0.37 4.7 ± 0.23 P = 0.008
Soluble fibrin monomer com-
plexes
 – positive
 – negative
3
16
4
76
n. s.
D-dimer, 10–3g/l 2.8 ± 0.6 2.7 ± 0.5 n. s.
Fibrin /fibrinogen degradation 
products, 10–3g/l
11.2 ± 2.4 15.2 ± 3.1 n. s.
Hemoglobin, g/l 104.5 ± 4.5 91.8 ± 2.3 n. s.
Platelets, 109/l 188.5 ± 22.8 87.0 ± 11.3 P = 0.001
WBC, 109/l 4.98 ± 2.8 1.6 ± 0.3 P = 0.001
Clinical manifestation of SIRS, % 21.0 46.0 P = 0.045
Blood components transfusion:
Cryoprecipitate, ml/kg x day
n = 6
12.0 ± 2.5
n = 12
19.8 ± 6.0
n. s.
Platelets, ml/kg x day n = 4
7.3 ± 1.1
n = 40
9.1 ± 5.2
n. s.
Red blood cell, ml/kg x day n = 4
11.7 ± 1.9
n = 18
9.0 ± 1.1
n. s.
Factor VIII concentrate, 
ml/kg x day
n = 3
40.0 ± 15.0
n = 2
60.0 ± 11.0
n. s.
Interestingly�� we have found that a higher D-dimer 
level in patients with VTE was indistinguisha�le from 
level of those without. This finding reflects the hyper-
coagula�le state of cancer patient and is in agree-
ment with other studies showing increased D-dimer 
concentration in those [��]. �o D-dimer as la�oratory 
test seems to �e the indicator of hypercoagula�le state 
of patient rather than predictor of VTE.
The num�er of predisposing to throm�osis risk 
factors in �oth groups was identical — ���� ������4�����   
�Ta�le 4��. Duration of immo�ilization in controls and 
cases was the same: ���� ��������� and ���� ������4����� 
weeks respectively �P > �.����. �urprisingly�� dura-
tion of catheterization of central vein was shorter 
among cases: �.� ��.��8.��� weeks compared to 8.� 
��.���4.��� in controls �P = �.�46��.
Table 4. Catheter placement and location and causes of VTE in children 
with cancer
Patients
Cases
n = 19
Controls
n = 80
Signifi-
cance
Position of catheter at time of VTE, (%):
• v. cephalica, basilica dextr/sinistr
• v. subclavia dextr/sinistr
• v. jugularis dextr/sinistr
• v. femoralis
3 (16.0%)
11 (58.0%)
1 (5,0%)
4 (21.0%)
16 (20.0%)
63 (78.7%)
0
1 (1.3%)
n. s.
n. s.
n. s.
P = 0.0004
Location of VTE
• cephalica, basilica dextr/sinistr
• v. brachialis
• v. subclavia dextr/sinistr
• v. jugularis
• v. cava superior
• v. femoralis dextr/sinistr
• v. ileofemoralis
• v. poplitea
5
1
2
2
1
4
2
2
0
0
0
0
0
0
0
0
Cause of VTE:
• catheter-related VTE
• ulcer of soft tissue
• vein compression by tumor mass
• prolonged immobilization (> 3 weeks)
• both prolonged immobilization and 
indwelling femoral venous catheter
• unknown
• FVL and presence of antiphospho-
lipid antibodies
• FVL and catheterization
4 + 2
1
1
3
3
1
2
2
0
0
0
0
0
0
0
0
Duration of catheter placement, week 3 (1–8) 8 (3–14) P = 0.046
Duration of immobilization, week 2 (0–3) 2 (1–4) n. s.
Predisposing to VTE factors, number 3.0
(2.0–4.0)
3.0
(2.0–4.0)
n. s.
Catheterization of v. su�clavia dominated as a 
choice of venous access for patients of �oth groups. 
Also v. v. cephalica and �asilica in compared groups 
were catheterized equally frequently. We did not reveal       
any association �etween the throm�osis and catheteri-
zation of a�ove veins.
The facts of throm�osis located in the pool of v. ca-
va inferior after catheterization of femoral vein �� pa-
tients�� and su�clavian vein �� patient�� were reported. 
In control group femoral catheter was used only for 
� patient. The association �etween catheterization of 
femoral vein and the development of throm�osis was 
revealed for compared groups �Р = �.���4��. 
Location of venous throm�osis and position of 
catheter were the same among � of �� patients. Thus 
our study�� like others reports [�6����]�� confirmed as-
sociation �etween presence of central venous line and 
throm�osis. Two of those � cases had throm�osis of 
upper extremities�� in another two v. su�clavia was af-
fected�� the throm�osis of v. internal jugularis had arisen 
as a result of incorrect catheter placement in yet another 
two children and three of the patients had throm�osis in 
femoral segment of venous system. These latter ones 
were immo�ilized for over � weeks. Compression of v. 
cava superior �y tumor mass resulted in throm�osis 
in one child. 
For � children venous access did not correlate with 
the place of formation of �lood clot. All positive for FV 
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Leiden patients �4 out of �� studied cases�� �elong to this 
group. Four patients had throm�osis of lower extremi-
ties �vv. poplitea�� femoralis��. Duration of immo�ilization 
for all 4 children had exceeded � weeks. The throm�o-
ses of vv. cephalica and �asilica were registered in 4 
cases �catheter was placed in v. su�clavia��. In one case 
the throm�osis of femoral vein occurred in patient with 
CVL located in v. su�clavia. Two out of those � patients           
additionally had antiphospholipid syndrome�� while other 
cases and all controls were APA-negative.
Although the specific com�ination of acquired and 
genetic risk factors differed �etween patients�� detailed 
analysis of each episode of VTE allowed us to formulate 
leading cause of throm�otic complications for each 
studied case �see Ta�le 4��.
The listed facts allow us to speculate that the 
throm�osis in children with cancer does not depend on 
gender. �uch factors as clinical condition�� coagulation 
status�� volume of haemostatic therapy and presence    
of clinical evidence of sepsis�� as well as duration of 
catheterization are not significant as predisposing to 
throm�osis factors. 
Overall�� our study showed that the leading risk factors 
for VTE in children with cancer are prolonged immo�iliza-
tion or �oth immo�ilization and indwelling femoral venous 
catheter. Also mutation FV Leiden is associated with 
higher risk for VTE in children with cancer. Oncological 
patients affected with VTE during treatment are candi-
dates for genotyping assay for Factor V Leiden�� as the for-
mer may determine duration of anticoagulation therapy 
and administration of secondary prophylaxis. Mutation 
MTHFR C6����T is a widespread polymorphism and is of 
little practical significance without plasma homocystein 
measurement. It is also in agreement with other reports. 
Nevertheless�� authors �elieve that genetic �ackground 
has real influence on �lood coagulation processes and 
further studies may uncover new genes and genetic 
a�normalities underlying tendency to throm�osis.
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ТРОМБОэМБОлические ОслОЖНеНиЯ ВО ВРеМЯ лечеНиЯ  
У ПАЦиеНТОВ ОНкОлОГическОГО ПРОфилЯ 
ДеТскОГО ВОЗРАсТА
Цель: оценить вклад наследственной предрасположенности к тромбозу в формировании венозной тромбоэмболии у пациентов 
онкологического профиля детского возраста. Методы: ПЦР с последующим рестрикционным анализом. Результаты: 
показано достоверное повышение частоты встречаемости мутации Лейдена в группе больных с тромбозами по сравнению 
с контрольной группой (P = 0,0004). Мутация гена протромбина G20210A не выявлена в ходе исследования ни у одного 
из 99 обследованных пациентов, что свидетельствует о  низкой частоте встречаемости данной мутации в белорусской 
популяции. Мутация гена MTHFR C677T выявлена в группе больных и в контрольной с  примерно одинаковой частотой 
(47,4 и 55,0% соответственно). Выводы: такие факторы как тяжесть состояния пациента, коагуляционный статус, объем 
заместительной гемостатической терапии, наличие симптомов сепсиса, равно как и длительность катетеризации вен, не 
являются существенными в прогнозировании риска возникновения тромбоза. Показано, что ведущими факторами риска 
в возникновении тромбоэмболических осложнений у пациентов онкологического профиля детского возраста являются 
длительная гиподинамия или сочетание длительной гиподинамии и катетеризации бедренной вены, а также наличие мутации 
Лейдена. Больным онкологического профиля c развившимся венозным тромбозом на фоне лечения основного заболевания 
необходимо определение  мутации Лейдена, так как носительство последней позволяет определить на длительность 
антикоагулянтной терапии и проведение вторичной профилактики.
Ключевые слова: венозный тромбоз, рак, дети, фактор V Лейдена, протромбин G20210A, MTHFR C677T.
Copyright © Experimental Oncology, 2007
